Density-enhanced protein-tyrosine phosphatase-1 (DEP-1 also CD148) is a transmembrane molecule with a single intracellular PTP domain. It has recently been proposed to function as a tumor suppressor. We have previously shown that DEP-1 dephosphorylates the activated plateletderived growth factor (PDGF) b-receptor in a siteselective manner (Kovalenko et al. (2000) . J. Biol. Chem. 275, 16219-16226). We analysed cell lines with inducible DEP-1 expression for cellular functions of DEP-1. Several aspects of PDGFb-receptor signaling were negatively affected by DEP-1 expression. These include PDGFstimulated activation of inositol trisphosphate formation, Erk1/2, p21Ras, and Src. Activation of receptor-associated phosphoinositide-3 kinase activity and of Akt/PKB were weakly attenuated at early time points of stimulation. Inhibition of PDGF-stimulated signaling depended on DEP-1 catalytic activity. Importantly, DEP-1 inhibited PDGF-stimulated cell migration. The catalytically inactive DEP-1 C1239S variant enhanced cell migration and PDGF-stimulated Erk1/2 activation, suggesting a dominant negative interference with endogenous DEP-1. In contrast to cell migration, cell-substrate adhesion was promoted by active DEP-1 and delayed or suppressed by DEP-1 C1239S, correlating with positive effects of DEP-1 on adhesion-stimulated Src kinase. We propose that negative regulation of growth-factor stimulated cell migration and promotion of cell-matrix adhesion may be related to the function of DEP-1 as tumor suppressor.
Introduction
Density-enhanced phosphatase-1 (DEP-1), also designated CD148, PTP-Z, PTPrj, and ECRTP, is a class III transmembrane protein-tyrosine phosphatase (PTP). It is composed of an extracellular domain containing eight type III fibronectin repeats, a transmembrane segment, and a single intracellular catalytic domain. DEP-1 is expressed in various cell types including all hematopoietic lineages, endothelial cells, fibroblasts, different epithelial, and smooth muscle cells (Ö stman et al., 1994; Borges et al., 1996; de la Fuente-Garcia et al., 1998; Autschbach et al., 1999; Schraven, 2000) . DEP-1 activity is enhanced by an as yet unidentified component of extracellular matrix (So¨rby et al., 2001) . As intracellular interaction partners, the PDZ protein syntenin and a 64 kDa serine/threonine kinase have been described (Jallal et al., 1997; Iuliano et al., 2001) . The widespread expression of DEP-1 suggests its involvement in diverse signaling pathways. The physiological functions of DEP-1 are, however, elusive. Upregulation of DEP-1 expression at high cell densities in WI-38 human embryonic lung fibroblasts and upon cell differentiation of ZR75 mammary carcinoma cells as well as low expression levels in thyroid tumors compared to normal thyroid tissue may indicate a possible negative role of DEP-1 in regulation of cell proliferation and transformation. Consistent with such a role, DEP-1 expression in mammary carcinoma cell lines and in thyroid carcinoma cells suppresses the transformed phenotype (Keane et al., 1996; Hundt and Schmidt, 1997; Zhang et al., 1997; Tangye et al., 1998a; Iuliano et al., 2003) . Recently, positional cloning of the mouse colon cancer susceptibility gene Scc1 revealed its identity with PTPRJ, encoding murine DEP-1. Frequent deletion of the PTPRJ gene in human cancers suggests a role of DEP-1 as a tumor suppressor (Ruivenkamp et al., 2002) . In T lymphocytes, DEP-1 expression is upregulated as a consequence of T-cell receptor stimulation in peripheral T lymphocytes. On the other hand, DEP-1 potently downregulates T-cell receptor signaling in Jurkat cells. This has been associated with dephosphorylation of phospholipase Cg and the adaptor molecule LAT (de la Fuente-Garcia et al., 1998; Tangye et al., 1998b; Baker et al., 2001) . Other DEP-1 substrates of potential physiological importance, which have recently been detected using a 'substrate trapping' approach, are the component of cell-cell adhesion complexes p120 ctn (Holsinger et al., 2002; Palka et al., 2003) , and the receptor tyrosine kinase Met (Palka et al., 2003) .
Platelet-derived growth factors and their cognate receptors are important regulators of cell proliferation, cell migration, cell differentiation, and cell-matrix interactions (Heldin et al., 1998; Heldin and Westermark, 1999; Ro¨nnstrand and Heldin, 2001 ). Disturbance of platelet-derived growth factor (PDGF) and PDGF receptor function has been associated with different diseases, including malignancies. Hitherto, relatively little is known about regulation of PDGF receptor signaling by PTPs. However, PTPs appear to play an important role in negative regulation of receptor function (Chiarugi et al., 2002; Ö stman and Bo¨hmer, 2001) .
We have reported earlier that DEP-1 can dephosphorylate the platelet-derived growth factor b-receptor. Dephosphorylation occurs in a site-selective manner, both in vitro and in intact cells, with phosphotyrosines 1009/1021 and phosphotyrosine 857 being the most and the least susceptible, respectively (Kovalenko et al., 2000; Persson et al., 2002) .
The possibility that DEP-1 modulates PDGF-receptor signaling is intriguing. We have now employed cell lines with inducible DEP-1 expression to analyse the effects of DEP-1 on PDGF-induced signaling. DEP-1 inhibits PDGF-stimulated Ras-and Erk1/2 activation as well as inositol trisphosphate (IP3) production. The PDGF-stimulated PI3-K-Akt/PKB pathway is affected with lower efficiency. Active wildtype (wt) DEP-1 markedly inhibits PDGF-stimulated cell migration in a modified Boyden-Chamber assay, whereas catalytically inactive DEP-1 C1239S enhances migration. Conversely, we observed enhanced cell-matrix adhesion in DEP-1-wt-expressing cells and reduced adhesion in DEP-1-CS-expressing cells. While a negative effect of DEP-1 on PDGF-induced cell migration is consistent with its negative effect on PDGF receptor signaling, the enhanced cell adhesion may be related to accelerated activation of Src-kinase upon attachment of DEP-1-expressing cells.
Results

DEP-1 is a negative regulator of PDGF-stimulated cell migration
Since DEP-1 downregulates PDGFb-receptor autophosphorylation in a phosphorylation site-selective manner, we were interested in the effects of DEP-1 on PDGFtriggered biological effects. Cell lines with inducible DEP-1 expression are ideally suited for this purpose, since clonal variations can largely be ruled out and expression is closer to physiological levels. Previously, we already described porcine aortic endothelial (PAE) cell lines, which constitutively express PDGFb-receptor, and in addition VSV-tagged DEP-1 in an inducible manner (Kovalenko et al., 2000) . In order to study the effects of DEP-1 also on cells with endogenous PDGF receptor expression, we additionally established NIH3T3 fibroblast cell lines that express either (untagged) DEP-1 wt or the catalytically inactive DEP-1 C1239S. This was accomplished by transfection with corresponding expression constructs in the tetracyclineregulated tricistronic expression vector pNRTIS33. Inducible expression of either DEP-1 wt or DEP-1 CS is shown for some fibroblast cell clones in Figure 1a . The different NIH3T3 clones have similar PDGF receptor levels, which were not altered in absence or presence of ATC (not shown). For comparison, expression of DEP-1 in a PAE cell line used throughout this study (X23) is also shown. Expression is detectable in the absence of anhydrotetracyline (ATC), and suppressed in the presence of ATC. The endogenous murine DEP-1 is not recognized by the antibody used. To obtain an estimate for the extent of DEP-1 overexpression in the transfected lines, we, therefore, evaluated the expression levels in two human fibroblast cell lines, 293 human embryonal kindney cells and hTERT BJ1 immortalized human foreskin fibroblasts (Figure 1b ). Compared to these levels, quantification revealed in the induced state 2.5-5-fold, 1.5-3-fold, and 2-4-fold overexpression for DEP-1 wt in PAE cells, DEP-1 wt in NIH3T3 cells, and DEP-1 CS in NIH3T3 cells, respectively.
We then analysed biological properties of the cell lines. Growth rates of the cell clones were largely unaltered, both at low and high serum conditions, and regardless of the absence or presence of DEP-1 wt or DEP-1 CS. Since PDGF stimulated DNA synthesis in Figure 1 Inducible DEP-1 expression in stable cell lines. NIH3T3 cells were transfected with DEP-1 wt or with DEP-1 C1239S mutant in the tricistronic tetracyline-regulated expression vector pNRTIS33. The PAE cell line X23 is stably transfected with a PDGFb-receptor expression construct and DEP-1 wt with a VSV tag and has been described earlier. The cells were grown in the presence ( þ ATC, suppression of expression) or absence (ÀATC, induction of expression) of ATC. Lysates from the different indicated clones were subjected to immunoblotting with anti-DEP-1 antibody 143.41. (a) Comparison of different cell clones with inducible DEP-1 expression, (b) Comparison of expression levels in inducible cell clones with endogenous DEP-1 levels in human HEK 293 and hTERT BJ1 fibroblasts. Note that two isoforms of DEP-1 with different mobility are detected whose proportions vary in the different cell lines. Similar amounts of loaded cell protein were verified by immunoblotting with anti-actin antibodies as indicated DEP-1 modulates cell migration and adhesion E Jandt et al our cell clones only weakly, we could not obtain reliable data for the effect of DEP-1 under these conditions (not shown). In contrast, all cell lines exhibited a pronounced PDGF stimulation of cell migration, assayed with the modified Boyden-Chamber test. Stimulation of migration could be seen already with 3 ng/ml PDGF-BB, and stimulation by 30 ng/ml was comparable or even exceeded the response obtained with 10% fetal calf serum (Figure 2a, c) . Expression of DEP-1 wt, both in PAE cells (Figure 2a ) and NIH3T3 cells (Figure 2c ), reduced PDGF-stimulated migration at all PDGF concentrations. At 3, 10, and 30 ng/ml PDGF, migration of DEP-1-expressing PAE cells was reduced to 44.8718.1, 70.9715.5, and 72.5716 .2%, respectively, compared to cells with suppressed DEP-1 expression (P in all cases o0.002 for eight independent experiments). Interestingly, migration was also attenuated by DEP-1 when FCS was used for stimulation (Figure 2a, c) . We recently described a novel selective PDGF receptor tyrosine kinase inhibitor D-65495 (Mahboobi et al., 2002) , which potently inhibits PDGFa-and b-receptor and Flt3, but has little activity toward a large panel of other protein kinases. D-65495 suppressed FCS-stimulated migration of PAE cells to a large extent (Figure 2b ), suggesting that much of the migration stimulation by FCS requires activation of PDGF receptor. In agreement, AG1296, another selective inhibitor of PDGF receptor kinase (Kovalenko et al., 1994) , also inhibited FCS-stimulated cell migration ( Figure 2b ). Little effect of DEP-1 expression on migration remains in the presence of the inhibitors, consistent with the concept that DEP-1 inhibits migration by downregulation of PDGF receptor signaling. Interestingly, expression of catalytically inactive DEP-1 CS resulted in an even enhanced PDGFstimulated migration of respective fibroblasts ( Figure 2c ). Again, migration in the presence of FCS was likewise elevated. Collectively, these data suggest that DEP-1 is a negative effector of growth factor-stimulated cell migration and that this function requires DEP-1 catalytic activity.
DEP-1 is a positive effector of cell adhesion
In the course of the migration assays, we observed that DEP-1-CS-expressing cells -despite their elevated migration -in some experiments poorly adhered to the collagen-coated membrane. Also, DEP-1-wt-expressing cells exhibited a flatter morphology and were more difficult to trypsinize than their nonexpressing counterparts (M Kovalenko, E Jandt; unpublished observation). Effects of several PTPs on cell-matrix adhesion have been described earlier, including positive effects of RPTPa (Harder et al., 1998) and PTP-1B (Cheng et al., 2001) . These findings led us to test whether DEP-1 has an effect on cell-matrix adhesion. Indeed, fibroblasts expressing DEP-1 wt adhered faster to collagen-coated plates than the same cells under conditions of suppressed DEP-1 wt expression (Figure 3a) . In contrast, DEP-1 CS expression led to an attenuation of cell attachment, both with respect to time-course and total Figure 3a ). These strong differences were observed when adhesion experiments were carried out in the absence of serum ( Figure 3a ). In presence of serum, adhesion was much faster and reached a plateau already after 15 min. Still, the same qualitative effects of DEP-1 on adhesion were observed, albeit the effects were smaller (not shown). The positive effect of DEP-1 was also apparent, when adhesion to fibronectin-coated plates was tested or when the plates remained uncoated (data not shown). As in the fibroblasts, also in PAE cells DEP-1 wt expression led to an accelerated adhesion to collagen-coated plates ( Figure 3b ). In this case, the effect was smaller and no effect on the final amount of adhered cells was observed. In summary, DEP-1 positively affects cell-matrix adhesion. Importantly, this effect depends again on the catalytic activity of DEP-1.
DEP-1 attenuates PDGF receptor-mediated signaling
To elucidate the possible targets for DEP-1 in inhibition of PDGF-stimulated cell migration, we analysed the effect of DEP-1 on selected signaling events in PAE cells. The established mediators of motogenic stimulation downstream of the PDGFb-receptor include PLCg and PI3-K (Heldin et al., 1998; Ro¨nnstrand et al., 1999b) . It is also known that DEP-1 is able to dephosphorylate the PDGFb-receptor phosphorylation sites, P-Tyr 751 and P-Tyr 1009/1021 , which are required for activation of PI3-K and PLCg, respectively (Kovalenko et al., 2000) . Therefore, we first analysed the effect of DEP-1 on PDGF-induced activation of PLCg and PI3-K. PLC activation was assessed by measuring PDGFstimulated IP3 formation. As shown in Figure 4a , IP3 formation in PAE cells was stimulated by PDGF in a dose-dependent manner. Expression of DEP-1 strongly reduced this response to nearly background levels. PI3-K activity was measured in PDGF receptor immunoprecipitates from PAE X23 cells. As expected, PI3-K activity in this assay depended on stimulation with PDGF. DEP-1 expression attenuated the PI3-K response at 3 and 7 min of stimulation ( Figure 4b ). Consistent with these observations, expression of DEP-1 in PAE X23 strongly reduced the association of PLCg1 to the PDGFb-receptor, whereas association of p85 was also attenuated albeit to a lesser extent ( Figure 4c ). As described earlier, DEP-1 expression reduced the level of PDGFR tyrosine phosphorylation ( Figure 4c ). We also looked at PDGF-stimulated phosphorylation of Akt/ PKB kinase, a known effector molecule downstream of PI3-K. In PAE X23 cells ( Figure 5a ) and also in DEP-1-wt-expressing fibroblasts (Figure 5b ), PDGF-stimulated Akt/PKB phosphorylation was reduced at 7 min of stimulation in DEP-1-wt-expressing cells (72 and 10% of control, normalized to detectable Akt level in PAE X23 and F2 2 cells, respectively), but seemed unaffected at later time points. DEP-1 CS expression had no obvious effect on Akt/PKB activation ( Figure 5c ).
We were also interested to elucidate the effects of DEP-1 on activation of Ras and Erk1/2. This pathway has been implicated in stimulation of cell proliferation by many growth factors as well as in stimulation of cell migration (Klemke et al., 1997; Ro¨nnstrand et al., 1999a) . To assay Erk1/2 activation, lysates from PDGFstimulated cells were subjected to immunoblotting with an antibody, specifically recognizing the activated, phosphorylated forms of p42/ Erk1 and p44/ Erk2. DEP-1 wt expression strongly reduced the intensity of Erk1/2 phosphorylation (Figure 5a,b) . In contrast, the fibroblasts expressing DEP-1 CS showed an elevated Erk1/2 activation (Figure 5c ). The conserved pathway of Erk1/2 activation involves activation of p21 Ras as a (Figure 6b ). Another important signaling event at the PDGFb-receptor is the binding and activation of Src-family kinases. It plays a role for PDGF-stimulated proliferation (Courtneidge et al., 1993; Roche et al., 1995; Hansen et al., 1996; Blake et al., 2000) as well as migration (Klinghoffer et al., 1999) . It is not yet known, whether phosphorylation of the Src-family kinase binding sites in the juxtamembrane domain of the PDGFb-receptor is affected by DEP-1. Kinase activity of immunoprecipitated Src from PAE cells was elevated upon prior PDGF stimulation of the cells (Figure 7) . Again, DEP-1 expression reduced the activation. In summary, several PDGF-stimulated signaling events are negatively modulated by DEP-1. The extent of modulation is, however, differential. Most prominent effects are seen on PLCg, Ras, and Erk1/2 activation, whereas PI3-K-Akt/PKB activation is only mildly affected.
Adhesion-dependent SRC activation is altered by DEP-1
Src is a component of focal adhesion complexes and plays an important role in the inside-outside and outside-inside signaling pathways regulating cell-matrix adhesion (Salazar and Rozengurt, 2001; Frame et al., 2002) . Positive effects of RPTPa and PTP-1B on cellmatrix adhesion have previously been associated with PTP-mediated Src activation (Harder et al., 1998; Cheng et al., 2001) . We, therefore, investigated the effect of DEP-1 variants on Src activity in the context of cellmatrix adhesion. Cells were trypsinized and kept in serum-free medium for 30 min to silence adhesiondependent signaling. Then, adhesion to culture dishes was allowed for the indicated time points. Adhered and nonadhered cells were collected and extracted, and Src activity in Src immunoprecipitates was measured by an in vitro kinase assay. Src activity in cells without DEP-1 
Discussion
The PDGFb-receptor mediates mitogenic and motogenic signals in different cell types. As revealed by the analysis of knockout mice, this receptor plays a critical role for proliferation and migration of vascular smooth muscle cells in development. Failing recruitment of vascular smooth muscle cells to growing blood vessels in PDGFb-receptor knockout mice is associated with numerous cardiovascular abnormalities. In adults, stimulation of migration and proliferation of connective tissue cells by PDGF is involved in wound healing (Claesson-Welsh, 1996; Heldin and Westermark, 1999) . We employed PAE and NIH3T3 fibroblast cell lines with conditional DEP-1 expression to investigate the role of DEP-1 for PDGF receptor signaling. As judged from comparison with endogenous DEP-1 levels in human fibroblasts, overexpression levels of DEP-1 in the induced state are only moderate in the NIH3T3 cell clones. We, therefore, believe that the results obtained with these cell clones are physiologically relevant.
Since it was known that DEP-1 downregulates PDGF receptor autophosphorylation, we expected that DEP-1 would also negatively affect biological outcomes of PDGF receptor stimulation. We show here that this is indeed the case for PDGF-stimulated cell migration. This conclusion is drawn based on the finding that two different cell types migrate to a lesser extent in case of induced DEP-1 expression. Importantly, it is also based on elevated migration of cells expressing the catalytically inactive DEP-1 CS mutant. Fibroblasts and endothelial cells express DEP-1 endogenously (Figure 1 ; Borges et al., 1996; Takahashi et al., 1999) . DEP-1 CS may compete with endogenous DEP-1 for substrates that are relevant for migration.
In keeping with inhibition of PDGF-stimulated cell migration, DEP-1 inhibits two PDGF-dependent signaling events that have previously been implicated in stimulation of migration: PLCg activation and PI3-K activation (Ro¨nnstrand and Heldin, 2001 ). Reduction of the PDGF-stimulated PI3-K activation is, however, transient, and does not translate into a sustained reduction of Akt/PKB activation. A similar observation has been reported earlier for the effect of PTP1B on insulin signaling in adipocytes. Expression of PTP1B inhibited PI3-K activation, but had little effect on Akt/ PKB (Venable et al., 2000) . The overall attenuation of this pathway by DEP-1 appears, thus, relatively inefficient. This observation may be related to results of the previous analysis of PDGFb-receptor dephosphorylation, which had shown that the PLCg binding site is the best substrate site in the phosphorylated receptor and that the binding site for the PI3-K p85 subunit is also dephosphorylated, but less efficiently (Kovalenko et al., 2000) . In agreement with the site Figure 7 DEP-1 inhibits PDGF-stimulated Src activity. X23 PAE cells were grown in the absence or presence of ATC as indicated, starved, and treated for different lengths of time with 50 ng/ml PDGF-BB. Src was immunoprecipitated from the lysates with agarose-coupled anti-Src antibody, and an in vitro kinase assay was performed with acid-denatured enolase and [ 32 g]ATP as substrates. The samples were subjected to SDS-PAGE and autoradiographic analysis using a PhosphorImager. The data are from a single experiment, which is representative for four with consistent results. In the lower panel, Src amounts in the immunoprecipitates as revealed by immunoblotting are shown (Figure 4c ). In addition, it is also possible that PLCg is a direct substrate of DEP-1. In DEP-1-overexpressing Jurkat cells, PLCg was hypophosphorylated, whereas little effects of DEP-1 were seen on phosphorylation of upstream kinases (Baker et al., 2001) . PDGF receptor-mediated activation of Src-family kinases has also been linked with PDGFstimulated cell migration. Immortalized murine fibroblasts, which are devoid of Src, Fyn, and Yes kinases, fail to migrate in response to PDGF (Klinghoffer et al., 1999) . Interestingly, DEP-1 expression also reduced PDGF stimulation of Src kinase in our experiments. Potentially, DEP-1 may affect receptor-Src interaction or could directly affect Src activity. However, treatment of cells with the selective Src inhibitor SU6656 (Blake et al., 2000) only weakly attenuated cell migration to 7575% of control, suggesting that interference with Src activation may not be a major mechanism for inhibition of migration by DEP-1.
Taken together, downregulation of PDGF-stimulated cell migration by DEP-1 is possibly the combined result of interference with not only one relevant signaling event. Major effects may, however, be exerted through inhibition of PLCg activation and inhibition of the Ras/ Erk pathway. Interestingly, DEP-1 also reduces FCSstimulated cell migration. It is currently not known which tyrosine kinases are important for the motogenic effect of FCS. It is possible that the PDGFb-receptor plays an important role. This is indicated by inhibition of FCS-stimulated migration with D-65495 and AG1296, two potent and selective PDGF-receptor tyrosine kinase inhibitors of different structural families (Kovalenko et al., 1994; Mahboobi et al., 2002) . Alternatively, or in addition, DEP-1 may affect migration by dephosphorylating other substrates, for example, other involved receptor tyrosine kinases, substrates downstream of the PDGF receptor, or substrates downstream of other surface receptors. Our attempts to test a number of alternative motogens, including FGF, IGF-1, lysophosphatidic acid, or VEGF on our cell lines, were unsuccessful, since none of them stimulated migration effectively (E Jandt, unpublished data). One could speculate that DEP-1 may also affect cell migration elicited by other receptors in other cell types. An interesting possibility is, for example, migration of endothelial cells, where DEP-1 is expressed to high levels (Borges et al., 1996; Takahashi et al., 1999) . Also, interaction of the Met/HGF-receptor with DEP-1 was described recently (Palka et al., 2003) . Similar as in case of the PDGFb-receptor, C-terminal phosphotyrosines in the Met cytoplasmic domain are preferred substrates of DEP-1. Biological consequences of Met-DEP-1 interaction have not yet been investigated (Palka et al., 2003) .
DEP-1 very effectively inhibits PDGF-dependent Rasand Erk1/2 activation. This may occur via dephosphorylation of SHC or Grb2 binding sites in the PDGFb-receptor. DEP-1-mediated dephosphorylation of these sites remains to be analysed. The Ras-Erk1/2 pathway is believed to be of general importance for stimulation of mitogenesis. Other signaling pathways also critically contribute to PDGF-induced mitogenesis (Heldin et al., 1998) . Notably, activation of Src-family kinases appears to be an important event in mitogenic stimulation by the PDGFb-receptor (Blake et al., 2000) . Still, we expected that the pronounced downregulation of Ras and Erk1/2-activation by DEP-1 would translate into reduced cell proliferation. The low mitogenic response of our cell clones to PDGF precluded the analysis of a possible DEP-1 effect. Basal proliferation in different concentrations of serum was not affected by DEP-1. It is potentially possible that cell clones with susceptibility to DEP-1 in terms of proliferation inhibition have been lost in our selection procedure, which required selection in presence of DEP-1 (see Materials and methods). Baker et al. (2001) recently reported that DEP-1 overexpression potently inhibits proliferation of Jurkat cells and selection under conditions of DEP-1 expression was not possible. The failure of DEP-1 to inhibit cell growth in our fibroblast and porcine aortic endothelial cell lines may alternatively be cell-type specific or relate to the only weak effect of DEP-1 on PDGF-stimulated PI-3 K and Akt/PKB activation.
Conversely to its inhibitory effect on cell migration, DEP-1 promoted cell-matrix adhesion. The DEP-1 extracellular domain contains fibronectin-like repeats and is structurally similar to cell-adhesion molecules. Also, functional interaction of DEP-1 with components of the extracellular matrix has been demonstrated (So¨rby et al., 2001) . One could, therefore, assume that the enhanced adhesion of DEP-1-expressing cells is mediated by the DEP-1 extracellular domain. However, cells expressing the catalytically inactive DEP-1 CS variant adhere in a delayed manner in the presence of serum and to strongly reduced extent in the absence of serum. Thus, positive effects of DEP-1 on cell adhesion clearly depend on DEP-1 catalytic activity. It is still possible, that the DEP-1 extracellular domain is involved in cell-substrate adhesion, but such a possible effect is then overridden in our assays by signaling events related to DEP-1 PTP activity. An important signaling molecule in focal adhesion complexes is Src kinase. Indeed, we observed a strongly reduced cell adhesion in the presence of the Src-selective tyrosine kinase inhibitor SU6656 (Blake et al., 2000) (E Jandt, unpublished observations). Interestingly, DEP-1 expression modulates adhesion-dependent Src activation. Acclerated adhesion in the presence of DEP-1 correlates with accelerated and enhanced activity of Src and delayed adhesion in presence of DEP-1 CS with delayed Src activation. It is tempting to speculate that Src activation occurs through DEP-1-mediated dephosphorylation of the Src C-terminal inhibitory phosphorylation site. Src kinase activation via such a mechanism has previously been shown for RPTPa and PTP-1B (Harder et al., 1998; Cheng et al., 2001) .
The differential effects of DEP-1 on different PDGFstimulated signaling events, on cell migration, and cellsubstratum adhesion support the concept that PTPs are DEP-1 modulates cell migration and adhesion E Jandt et al modulators rather than mere antagonists of tyrosine kinase-dependent signaling (Ö stman and Bo¨hmer, 2001 ). Interestingly, DEP-1 has recently been identified as the product of the mouse colon cancer susceptibility gene Scc1, and frequent deletion of the DEP-1 encoding gene occurs in human cancers (Ruivenkamp et al., 2002) . Also recently, characterization of mice expressing a catalytically inactive variant of DEP-1 has been reported. Homozygous animals die at day 10.5 of gestation as a consequence of severe vascular abnormalities. Elevated proliferation of endothelial cells and an altered endothelial-pericyte interaction have been proposed to form the basis for these defects (Takahashi et al., 2003) . It is possible that the here described roles of DEP-1 in negative regulation of cell migration and positive regulation of cell-matrix adhesion contribute to its putative tumor suppressor activity and to the vascular abnormalities in mice with compromised DEP-1 function.
Materials and methods
Materials
NIH 3T3 cells were obtained from the American Type Culture Collection (Manassas, VA, USA). PAE cells, stably expressing PDGFb-R and inducibly expressing DEP-1, were obtained as described earlier (Kovalenko et al., 2000) . hTERT BJ1 immortalized human foreskin fibroblasts were purchased from Clontech (Heidelberg, Germany). The monoclonal antibody 143.41 against the DEP-1 (CD148) extracellular domain (de la Fuente-Garcia et al., 1998) was kindly provided by Dr Jordi Vives (Barcelona, Spain). Antiphospho-Akt and antiphosphop42/p44 Erk antibodies were from Cell Signaling Technology (Frankfurt am Main, Germany), the anti-pan-Erk antibody was from Transduction Laboratories (Heidelberg, Germany), the anti-Akt1 antibody was from BD PharMingen International (Heidelberg, Germany), anti-Ras antibodies (antipan-Ras, anti-K-Ras, anti-H-Ras, anti-N-Ras), anti-PDGF b-receptor (958), anti-Src antibody for immunoblotting (SRC2), anti-phosphotyrosine antibodies PY99, anti-mouse-HRP, and anti-rabbit-HRP antibodies were from Santa Cruz Biotechnologies (Santa Cruz, CA, USA). Anti-v-src (Ab1, clone 327) antibody agarose-linked for immunoprecipitation, was from Calbiochem-Novabiochem (Bad Soden, Germany). Anti-hPDGFb-receptor monoclonal antibodies (Ro¨nnstrand et al., 1988) and anti-PLCg1 antibodies (Arteaga et al., 1991) were described earlier. Anti-p85 antibodies were from Upstate Biochemicals (Lake Placid, NY, USA). Human PDGF-BB was from Peprotech and purchased from TEBU (Frankfurt, Germany), TypeI collagen was from PromoCell (Heidelberg, Germany).
Constructs for inducible DEP-1 expression
The vector pNRTIS33 (Tenev et al., 2000) allows eukaryotic expression of the gene of interest, the neomycin resistance gene, and the gene for the tetracycline responsive transactivator (tTA) in a tricistronic cassette under control of a tetracycline responsive promotor. wt DEP-1 and the DEP-1 C1239S mutant were subcloned from previously described plasmids (Ö stman et al., 1994; Gross et al., 1999) into the EcoRI restriction site of the pNRTIS33 by standard techniques. The resulting expression constructs were designated pNRTIS33-DEP-1wt and pNRTIS33-DEP-1CS.
Cell culture and transfection
NIH 3T3 cells were cultivated in Dulbecco's modified Eagle medium (DMEM), supplemented with 10% newborn calf serum (NCS) in 5% CO 2 humidified atmosphere. PAE cells, constitutively expressing the PDGFb-R and inducibly expressing wt DEP-1, were cultivated in DMEM with 10% fetal calf serum and 200 mg/ml hygromycin. Transfection of NIH3T3 cells with pNRTIS33-DEP-1Wt, pNRTIS33-DEP-1CS or pNRTIS33 (mock control) was performed using Lipofectamine Plus reagent (Invitrogen, Karlsruhe, Germany), and stable clones were selected in the absence of ATC with 600 mg/ ml G418. The clones were screened for inducible expression by growing cells in presence or absence of 100 ng/ml ATC followed by immunoblotting of the corresponding lysates with anti-DEP-1 antibody.
Immunoblotting
If not otherwise specified, cells were grown in six-well plates under the conditions described above, with or without ATC, near to confluency. Appropriately treated cells were lysed in 0.5 ml lysis buffer (50 mm HEPES pH 7.5, 150 mm NaCl, 1.5 mm MgCl 2 , 1 mm EDTA, 1% Triton X-100, 1% sodium deoxycholate, 0.1% SDS, 10% glycerol, 10 mm sodium pyrophosphate, 1 mg/ml leupeptin, 1 mg/ml pepstatin, 200 KIE/ml aprotinin, 1 mm phenylmethylsulphonyl fluoride (PMSF), 1 mm benzamidine, 0.1 mg/ml Pefabloc (Roche, Mannheim, Germany), 1 mm dithiothreitol, 1 mm sodium orthovanadate). Lysates were cleared by centrifugation at 20 000 g for 25 min. For immunoblot analysis, samples were run on 7.5, 10, or 13% SDS polyacrylamide gels, and the separated proteins were transferred onto PVDF membranes (2 mA/cm2, 25 V, 1.5 h). Membranes were blocked in NET-G-T (50 mm TRIS-HCl pH 7.5, 150 mm NaCl, 5 mm EDTA, 0.02% gelatine, 0.05% Tween20) for 1 h and incubated with the primary antibodies diluted in NET-G-T overnight at 41C. After washing with NET-G-T, membranes were probed with secondary antibodies in NET-G-T and developed with Western Lightning (NEN Life Sciences, Cologne, Germany) or Super Signal (Perbio Science, Bonn, Germany) chemiluminescence kits.
Analysis of PDGF-stimulated signaling
Cells were grown with or without ATC in six-well dishes and serum-starved for 7 h. The cells were left unstimulated or were stimulated with 50 ng/ml PDGF-BB. Lysates were prepared as described and tested for levels of PDGF-receptor and cell protein by immunoblotting with anti-PDGF receptor antibodies and anti-actin antibodies, respectively. For detection of Erk1/2 activation or Akt/PKB activation, lysate aliquots were subjected to immunoblotting with the respective phosphospecific antibodies. Then the blots were stripped and reprobed with phosphorylation-independent antibodies.
To measure the PDGF-stimulated Src activity, Src was immunoprecipitated from the lysates with anti-v-Src-antibody beads (2 ml blended with 15 ml Sepharose CL-4B per extract of one dish) at 41C for 3 h. Aliquots (10%) of the immunoprecipitates were subjected to immunoblotting with anti-Src antibodies. The beads were washed three times with lysis buffer, twice with kinase buffer (100 mm HEPES pH 7.4; 10 mm MgCl 2 ; 10 mm MnCl 2 ; 200 mm b-mercaptoethanol), suspended in 37 ml kinase buffer. Substrate mix (4 ml) containing [g 32 P]ATP (5 mCi, 25 mm final concentration) and 5 mg acid-denatured enolase (Cooper et al., 1984) were added. The kinase reaction was allowed at 301C for 1 h and was stopped with 10 ml SDS-PAGE sample buffer (6% SDS, 30%
DEP-1 modulates cell migration and adhesion E Jandt et al b-mercaptoethanol, 40% glycerol, bromophenol blue), proteins were separated by electrophoresis on a 10% gel. The gel was Coomassie-stained, dried, and subjected to autoradiography. Precipitates with beads alone were devoid of kinase activity. The Src-selective inhibitor SU6656 inhibited the majority of detected Src activity, proving the specificity of the assay.
To monitor Ras activation, activated GTP-bound Ras was captured with a GST-fusion protein containing the Ras binding domain of Raf (GST-Raf-RBD). The pull down was carried out as described (de Rooij and Bos, 1997) with some modifications. Briefly, the stimulated cells were lysed in Raspulldown buffer (50 mm Tris/HCl pH 7.5, 1 mm EGTA, 150 mm NaCl, 5 mm MgCl 2 , 1% NP-40, and inhibitors as in lysis buffer) containing 100 mm GDP and 20 mg GST-Raf-RBD. The lysates were cleared by centrifugation at 20 000 g for 15 min, and then incubated with GSH sepharose beads by endover-end rotation at 41C for 30 min. The beads were washed three times with Ras-pulldown buffer and analysed for bound GTP-Ras proteins by SDS-PAGE using 13% gels and immunoblotting with a mixture of different anti-Ras antibodies (anti-pan-Ras, anti-K-Ras, anti-H-Ras, anti-N-Ras, each 1 : 100 in NET-G-T). Coomassie staining of GST-Raf-RBD in the pulldown material was performed to control equivalent precipitation. No Ras was precipitated in the absence of GST-Raf-RBD.
To assay PDGFb-receptor-associated PI-3-kinase, PDGFbreceptor was immunoprecipitated from the complete cell lysate of one well in a six-well plate using 1 mg of an anti-PDGFbreceptor antibody at 41C for 3 h. Aliquots of corresponding immunoprecipitates were subjected to analysis of PDGF receptor levels by immunoblotting. The collected beads were washed twice with PBS/1% NP-40, once each with PBS, 0.1 m Tris-HCl pH 7.5/0.5 m LiCl, distilled water, and 25 mm HEPES pH 7.5/100 mm NaCl/1 mm EDTA, and were finally suspended in 25 mm HEPES pH 7.5/100 mm NaCl/1 mm EGTA, containing 0.2 mg/ml presonicated phosphatidylinositole as substrate. After 10 min incubation at room temperature, an ATP mix was added containing [g 32 P]ATP (5 mCi), ATP (200 mm, final concentration), and MgCl 2 (10 mm, final concentration). The kinase reaction was allowed for 20 min and then stopped with 100 ml chloroform-methanol-HCL (50 : 100 : 1), followed by extraction of the phospholipids from the organic phase. The lipids were concentrated in a Speed Vac, applied to a DC-plate (silica gel 60 plate, preimpregnated with water solution of 1% potassium oxalate), resolved by thin layer chromatography with chloroform-methanol-32% ammonia-water (43-38-4.5-7.5), and the plate was exposed to a PhosphoImager.
PDGF-stimulated IP3 formation was determined exactly as described earlier (Graness et al., 1997) . To analyse association of PLCg or p85 to PDGFb-receptors, X23 PAE cells were treated as described earlier (Kovalenko et al., 2000) , and PDGFb-receptor was immunoprecipitated from lysate of cells from one subconfluent 15 cm dish, using 2 mg each of B1 and B2 monoclonal antibodies (Ro¨nnstrand et al., 1988) . The immunoblot was cut and the corresponding parts of the blot were probed with anti-phosphotyrosine antibodies, antiPLCg1 antibodies, or anti-p85 antibodies.
Cell migration assay
Cells were grown in complete medium, trypsinized, and resuspended at a density of 8 Â 10 5 cells per milliliter in serum-free medium containing 2.5 mg/ml bovine serum albumin. The assay was performed in a modified Boyden chamber (48-well microchemotaxis chamber AP48, Neuro Probe, Inc.), where the same medium containing PDGF-BB in the indicated concentrations or medium with 10% FCS was added in the lower part. The wells were covered with a nucleopore polycarbonate membrane with a pore size of 8 mm (COSTAR), previously coated with 30 mg/ml collagen type I at 41C overnight, and air-dried. The chamber was assembled and about 4 Â 10 4 cells were added into each upper well. The chamber was then kept in a CO 2 incubator at 371C for 4 h. The chamber was disassembled and the cells on the membrane were fixed and stained in a solution of 0.5% crystal violet in 20% methanol. Cells on the upper surface of the membrane were removed using cotton swaps. The migrated cells on the membrane surface facing the lower chamber were quantified by counting. Samples were run as quadruplicates.
Cell adhesion assay
The assay was performed as described elsewhere (Chiarugi et al., 2000) . In brief, 96-well plates were coated with 30 mg/ml collagen type 1 (PromoCell, Heidelberg) at 41C overnight and washed twice with PBS. Cells were suspended at a density of 3 Â 10 5 cells per milliliter in serum-free medium or in medium containing 10% FCS, kept for 30 min in suspension, and then 100 ml cell suspension was added per well. Adhesion was allowed for different times and stopped by removal of the medium with nonadhered cells and addition of 0.5% crystal violet in 20% methanol for 5 min. The wells were washed twice with PBS, adhered cells were solubilized with 0.1 m sodium citrate (0.1 ml per well), and absorbance of solubilized cells was measured at 570 nm.
Adhesion-induced SRC activation
Cells were prepared as described by Cheng et al. (2001) . Briefly, cells were trypsinized, washed twice with DMEM containing 0.1% NCS and 0.2% BSA, and 1 Â 10 7 cells were diluted in 10 ml of the same medium. After incubation at 371C for 30 min, 2 ml of the cell suspension was seeded per 35 mm dish. At the indicated time points, adhered and nonadhered cells were combined and lysed in 500 ml lysis buffer. Src immunoprecipitation and in vitro kinase reaction were done as described above.
